Vonjo receives orphan drug designation in Korea
By Eo, Yun-Ho | translator Kang, Shin-Kook
24.09.06 05:02:59
가나다라
0
MFDS announces its use for patients with platelet (blood clotting cells) levels below 50×10⁹/L
Demonstrated 35% or greater spleen volume reduction from baseline through Phase III PERSIST-2 trial
The oral myelofibrosis drug Vonjo has been designated as an orphan drug in Korea.
The Ministry of Food and Drug Safety announced so on the 3rd through an orphan drug designation.
Specifically, the drug is indicated for ‘adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)